Also known as: T-cell growth factor (TCGF) Interleukin-2 precursor IL-2

Active ingredient description

Aldesleukin, a lymphokine, is produced by recombinant DNA technology and acts as a regulator of the immune response. The biological activities of aldesleukin and native human IL-2, a naturally occurring lymphokine, are comparable. The administration of aldesleukin in murine tumour models has been shown to reduce both tumour growth and spread. The exact mechanism by which aldesleukin-mediated immunostimulation leads to antitumour activity is not yet known.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AC Interleukins
Discover more medicines within L03AC01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)

External identifiers

CAS Substance: 110942-02-4
DrugBank Drug: DB00041
RxNorm Ingredient: 70223
SNOMED-CT Concept: 386917000
Aldesleukin (substance)
UNII Identifier: M89N0Q7EQR


Aldesleukin is an active ingredient of these brands:

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

France (FR)

Netherlands (NL)

Singapore (SG)

Spain (ES)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.